NGeneBio

At a glance

NGeneBio filed 85 disclosures in the last 12 months, including 6 5% holder, 4 insider, 2 issuance and 2 m&a. The most recent key filing was on Oct 8: A major holder's stake fell from 5.26% to 0.00% (conversion/exercise).

Revenue for 2025 was ₩21.2B, up 278.5% on 2024. It made an operating loss of ₩8.3B. Debt was 220% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩24.4B and operating loss of ₩2.8B.

The 2025 annual report lists 56 employees with an average tenure of 3.6 years and average pay of ₩61.8M, #1042 of 2,191 listed companies by average pay. Its 6 directors and auditors were paid ₩171.3M each on average. It paid no cash dividend for 2025. 에스에이치헬스케어투자1호조합 and related parties held 23.51% at year end.

Of 5 recent 5%+ holder reports, 2 raised and 1 cut a stake; the largest stake reported was 29.66% on Sep 17.

From the 2025 annual report

Staff: 56 (24 men, 32 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩8.7B. Directors and auditors: 6, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

에스에이치헬스케어투자1호조합 holds 23.51%; with 0 related parties the group holds 23.51% of common shares at year end (from 0.00% at the start of the year).

Auditor: 삼도회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports